WO2016134234A1 - Methods, compositions, and kits for treatment of cancer - Google Patents
Methods, compositions, and kits for treatment of cancer Download PDFInfo
- Publication number
- WO2016134234A1 WO2016134234A1 PCT/US2016/018634 US2016018634W WO2016134234A1 WO 2016134234 A1 WO2016134234 A1 WO 2016134234A1 US 2016018634 W US2016018634 W US 2016018634W WO 2016134234 A1 WO2016134234 A1 WO 2016134234A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fgfr3
- inhibitor
- seq
- antibody
- antagonistic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 206010028980 Neoplasm Diseases 0.000 title claims description 89
- 238000000034 method Methods 0.000 title claims description 41
- 238000011282 treatment Methods 0.000 title description 46
- 201000011510 cancer Diseases 0.000 title description 43
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims abstract description 101
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims abstract description 101
- 229940125832 FGFR3 inhibitor Drugs 0.000 claims abstract description 76
- 239000012270 PD-1 inhibitor Substances 0.000 claims abstract description 36
- 239000012668 PD-1-inhibitor Substances 0.000 claims abstract description 36
- 229940121655 pd-1 inhibitor Drugs 0.000 claims abstract description 36
- 230000003042 antagnostic effect Effects 0.000 claims description 39
- 239000003446 ligand Substances 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 229960003301 nivolumab Drugs 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 8
- 229960002621 pembrolizumab Drugs 0.000 claims description 8
- 229950009791 durvalumab Drugs 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 abstract description 67
- 239000007787 solid Substances 0.000 abstract description 11
- 201000005787 hematologic cancer Diseases 0.000 abstract description 8
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 26
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 26
- 239000005557 antagonist Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 19
- 238000011161 development Methods 0.000 description 15
- 230000018109 developmental process Effects 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 230000003442 weekly effect Effects 0.000 description 15
- 230000004614 tumor growth Effects 0.000 description 13
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 10
- 102000037865 fusion proteins Human genes 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 108091008794 FGF receptors Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 150000003384 small molecules Chemical group 0.000 description 7
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 6
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 6
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 108091023037 Aptamer Proteins 0.000 description 4
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical group C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 4
- -1 Novartis) Chemical compound 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- KPJDVVCDVBFRMU-AREMUKBSSA-N (6r)-6-(2-fluorophenyl)-n-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine Chemical compound COCCNCCC1=CC=CC(NC=2N=C3C4=CC=CC=C4[C@H](C=4C(=CC=CC=4)F)CC3=CN=2)=C1 KPJDVVCDVBFRMU-AREMUKBSSA-N 0.000 description 3
- GKJCVYLDJWTWQU-CXLRFSCWSA-N 2-[4-[(e)-2-[5-[(1r)-1-(3,5-dichloropyridin-4-yl)ethoxy]-1h-indazol-3-yl]ethenyl]pyrazol-1-yl]ethanol Chemical compound O([C@H](C)C=1C(=CN=CC=1Cl)Cl)C(C=C12)=CC=C1NN=C2\C=C\C=1C=NN(CCO)C=1 GKJCVYLDJWTWQU-CXLRFSCWSA-N 0.000 description 3
- VRQMAABPASPXMW-HDICACEKSA-N AZD4547 Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)C=2)=C1 VRQMAABPASPXMW-HDICACEKSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- BEMNJULZEQTDJY-UHFFFAOYSA-N [5-amino-1-(2-methyl-3h-benzimidazol-5-yl)pyrazol-4-yl]-(1h-indol-2-yl)methanone Chemical compound C1=CC=C2NC(C(=O)C=3C=NN(C=3N)C=3C=C4N=C(NC4=CC=3)C)=CC2=C1 BEMNJULZEQTDJY-UHFFFAOYSA-N 0.000 description 3
- 238000011374 additional therapy Methods 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 229950004444 erdafitinib Drugs 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229950005712 infigratinib Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- OLAHOMJCDNXHFI-UHFFFAOYSA-N n'-(3,5-dimethoxyphenyl)-n'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-n-propan-2-ylethane-1,2-diamine Chemical compound COC1=CC(OC)=CC(N(CCNC(C)C)C=2C=C3N=C(C=NC3=CC=2)C2=CN(C)N=C2)=C1 OLAHOMJCDNXHFI-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008723 Chondrodystrophy Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 2
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 2
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229940124060 PD-1 antagonist Drugs 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000008919 achondroplasia Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 229940126546 immune checkpoint molecule Drugs 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 2
- 229960001131 ponatinib Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 229950007217 tremelimumab Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KGWWHPZQLVVAPT-STTJLUEPSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)-2-[(e)-2-phenylethenyl]pyrimidin-4-amine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(\C=C\C=2C=CC=CC=2)=N1 KGWWHPZQLVVAPT-STTJLUEPSA-N 0.000 description 1
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- PUIXMSRTTHLNKI-UHFFFAOYSA-N 6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-[3-(4-prop-2-enoylpiperazin-1-yl)propyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound C(C=C)(=O)N1CCN(CC1)CCCN1C(C(=CC2=C1N=C(N=C2)NC)C2=C(C(=CC(=C2Cl)OC)OC)Cl)=O PUIXMSRTTHLNKI-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000917148 Homo sapiens Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000005911 anti-cytotoxic effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229950005778 dovitinib Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 102000055709 human FGFR3 Human genes 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940034727 zelboraf Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present application is directed to methods, compositions, and kits that utilize a combination of FGFR3 inhibitor and PD 1 inhibitor to treat cancer.
- FGFR3 inhibitor binds FGFR3.
- the FGFR3 inhibitor binds a ligand for FGFR3.
- the FGFR3 inhibitor is an antagonistic FGFR3 antibody, and in certain of these embodiments the antagonistic FGFR3 antibody comprises one or more of a CDR-H1 comprising SEQ ID NO: 1, a CDR-H2 comprising SEQ ID NO:2, a CDR-H3 comprising SEQ ID NO:3, a heavy chain variable region comprising SEQ ID NO:7, a heavy chain comprising SEQ ID NO:9, a CDR-L1 comprising SEQ ID NO:4, a CDR-L2 comprising SEQ ID NO:5, a CDR-L3 comprising SEQ ID NO:6, a light chain variable region comprising SEQ ID NO:8, and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 10.
- the FGFR3 antagonistic antibody is B-701. In other embodiments, the antagonistic FGFR3 antibody is selected from the group consisting of PRO-001 and IMC- Dl 1.
- the FGFR3 inhibitor is a small molecule pan-FGFR inhibitor, and in certain of these embodiments the pan-FGFR inhibitor is selected from the group consisting of infigratinib, AZD4547, LY2874455, Debio 1347, ARQ 087, and JNJ-42756493.
- the PDl inhibitor binds PDl . In other embodiments, the PDl inhibitor binds a ligand for PDl .
- the PDl inhibitor is an antagonistic PDl antibody, and in certain of these embodiments the antagonistic PDl antibody is selected from the group consisting of nivolumab, pembrolizumab, CT-011, MEDI-0680, and RMPl- 14.
- the PDl inhibitor is an antagonistic PDl ligand antibody, and in certain of these embodiments the antagonistic PDl ligand antibody is selected from the group consisting of MEDI-4736, RG7446, BMS-936559, MSB0010718C, and MPDL3280A.
- compositions comprising an FGFR3 inhibitor and a PDl inhibitor.
- compositions are pharmaceutical compositions, and in certain embodiments the compositions comprise one or more pharmaceutically acceptable carriers.
- the FGFR3 inhibitor binds FGFR3. In other embodiments, the FGFR3 inhibitor binds a ligand for FGFR3.
- the FGFR3 inhibitor is an antagonistic FGFR3 antibody
- the antagonistic FGFR3 antibody comprises one or more of a CDR-H1 comprising SEQ ID NO: l, a CDR-H2 comprising SEQ ID NO:2, a CDR-H3 comprising SEQ ID NO:3, a heavy chain variable region comprising SEQ ID NO:7, a heavy chain comprising SEQ ID NO:9, a CDR-L1 comprising SEQ ID NO:4, a CDR-L2 comprising SEQ ID NO:5, a CDR-L3 comprising SEQ ID NO:6, a light chain variable region comprising SEQ ID NO:8, and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 10.
- the FGFR3 antagonistic antibody is B-701. In other embodiments, the antagonistic FGFR3 antibody is selected from the group consisting of PRO-001 and IMC- Dl 1.
- the FGFR3 inhibitor is a small molecule pan-FGFR inhibitor, and in certain of these embodiments the pan-FGFR inhibitor is selected from the group consisting of infigratinib, AZD4547, LY2874455, Debio 1347, ARQ 087, and JNJ-42756493.
- the PDl inhibitor binds PDl. In other embodiments, the PDl inhibitor binds a ligand for PDl .
- the PDl inhibitor is an antagonistic PDl antibody, and in certain of these embodiments the antagonistic PDl antibody is selected from the group consisting of nivolumab, pembrolizumab, CT-011, MEDI-0680, and RMPl- 14.
- the PDl inhibitor is an antagonistic PDl ligand antibody, and in certain of these embodiments the antagonistic PDl ligand antibody is selected from the group consisting of MEDI-4736, RG7446, BMS-936559, MSB0010718C, and MPDL3280A.
- kits comprising an FGFR3 inhibitor and a PDl inhibitor for use in treating cancer.
- the kits further comprise instructions for use.
- FGFR3 inhibitor and a PD 1 inhibitor for use in formulating a medicament for the treatment of cancer.
- the FGFR3 inhibitor and PDl inhibitor are formulated into a single
- the FGFR3 inhibitor and PDl inhibitor are formulated into separate medicaments which are administered in combination with one another.
- FIG. 1 Changes in tumor volume in MC38 syngeneic tumor mice following administration of FGFR3 and/or PD1 inhibitor antibodies.
- FIG. 2 A two week efficacy snapshot showing the changes in tumor volume in MC38 syngeneic tumor mice following administration of FGFR3 and/or PD1 inhibitor antibodies.
- FIG. 3 Changes in tumor volume in mice implanted with Lewis Lung Carcinoma tumor cells following administration of FGFR3 and/or PD1 inhibitor antibodies.
- FIG. 4 Changes in tumor volume in mice implanted with Madison 109 tumor cells following administration of FGFR3 and/or PD1 inhibitor antibodies.
- FGFR1-4 transmembrane tyrosine kinase fibroblast growth factor receptors
- FGFRs are overexpressed in many cancer types, often due to mutations that confer constitutive activation, making them an attractive target for therapeutic intervention.
- FPA144 FPA144
- Other FGFR2 monoclonal antibodies in early development for cancer treatment include GP369 (Aveo) and HuGAL-FR21 (Galaxy) (Zhao 2010; Bai 2010).
- a humanized anti- FGFR4 has also been reported to inhibit tumor growth (Bumbaca 2011).
- FGFR3 harbors both oncogenic and tumor suppressive properties. FGFR3 is frequently mutated in certain cancers, but in some normal tissues it can limit cell growth and promote cell differentiation (Lafitte 2013).
- the human FGFR3 antagonistic monoclonal antibody MFGR1877S (CAS No. 1312305-12-6), referred to herein as B-701 or BM2, was the first FGFR antibody to enter clinical development.
- B-701 is a lyophilized form of MGFR1877A.
- B-701 is currently in early development for the treatment of metastatic bladder cancer (urothelial cell carcinoma) and achondroplasia (dwarfism).
- B-701 was originally identified through phage display, then recombined with a human IgGl backbone.
- B-701 binds with high affinity to both wild-type and mutant FGFR3, including the most prevalent mutations found in bladder cancer and achondroplasia (specifically, FGFR3- mb R248C FGFR3 _nib K652E , FGFR3-III Y 75C , FGFR3-IIIb S249C , and FGFR3-IIIb G 72C ), while exhibiting no cross-reactivity with other FGFRs.
- B-701 was previously evaluated for safety in patients with t(4: 14) translocated multiple myeloma (Clinical Trial NCTOl 122875).
- FGFR3 inhibitor antibodies currently in clinical or preclinical development include PRO-001 (Prochon) and IMC-D11 (ImClone). Additional FGFR3 antibodies for use in treating cancer and other diseases have been disclosed in, for example, U.S. Patent Nos. 8,187,601 (Aveo) and 7,498,416 (Fibron).
- PD1 Programmed cell death protein 1
- PD1 is an immune checkpoint receptor from the CD28 superfamily that limits T cell effector functions within tissues following activation by either of its two ligands, PDLl or PDL2 (Pardoll 2012).
- PD1 downregulates the immune system by promoting apoptosis in antigen-specific T cells while reducing apoptosis in regulatory (i.e., suppressor) T cells.
- Certain tumor cells block anti-tumor immune responses in the tumor microenvironment by upregulating ligands for PD1. Blocking the PD1 pathway activates the immune system to attack tumors, and has been shown to induce sustained tumor regression in various tumor types.
- several PD1 antagonist antibodies are currently in various stages of clinical development.
- the fully human IgG4 monoclonal PD1 antibody nivolumab Opdivo®, Bristol-Myers Squibb and Ono
- a variety of PD1 ligand (PDL) antibodies are also in development for cancer treatment.
- the monoclonal IgGlk PDLl antibody MEDI-4736 (AstraZeneca) is currently in development for the treatment of NSCLC either alone or in combination with the monoclonal CTLA4 antibody tremelimumab (AstraZeneca) or MEDI-0680
- the monoclonal IgGlk PDLl antibody RG7446 (Roche) is in development for use in treating various cancers alone or in combination with Avastin® and Zelboraf®
- the fully human monoclonal IgG4 antibody BMS-936559/MDX-1105 (BMS) is currently in development for the treatment of NSCLC and other cancer types
- the fully human IgGl PDLl antibody MSB0010718C (Merck Serono) is in development for treating various cancer types
- the Fc-modified monoclonal IgGl antibody MPDL3280A (Genen
- kits for treating a solid or hematologic cancer in a subject in need thereof comprising administering an FGFR3 inhibitor and a PDl inhibitor.
- methods of increasing the effectiveness of a PDl inhibitor for treating cancer in a subject in need thereof comprising administering an FGFR3 inhibitor, as well as methods of increasing the effectiveness of an FGFR3 inhibitor for treating cancer in a subject in need thereof comprising administering a PDl inhibitor.
- An increase in effectiveness of a PDl or FGFR3 inhibitor may refer to an increase in the therapeutic effect of either inhibitor, a decrease in the required dosage, administration frequency, or administration interval of either inhibitor to obtain a particular level of therapeutic effect, or some combination thereof.
- solid cancer refers to a cancer that forms a discrete tumor mass.
- solid cancers within the scope of the present methods include cancers of the colon, rectum, kidney, bladder, prostate, brain, breast, liver, lung, skin (e.g., melanoma), and head and neck.
- hematologic cancer refers to cancers that occur in cells of the immune system or in blood-forming tissues including bone marrow and which generally do not form solid tumors.
- hematologic cancers within the scope of the present methods include leukemia (e.g., acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia), Hodgkin and non- Hodgkin lymphoma, myeloma, and myelodysplastic syndrome.
- leukemia e.g., acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia
- Hodgkin and non- Hodgkin lymphoma myeloma
- myeloma myelodysplastic syndrome
- the terms “treat,” “treating,” and “treatment” as used herein with regard to solid cancers may refer to partial or total inhibition of tumor growth, reduction of tumor size, complete or partial tumor eradication, reduction or prevention of malignant growth, partial or total eradication of cancer cells, or some combination thereof.
- the terms “treat,” “treating,” and “treatment” as used herein with regard to hematological cancers may refer to complete or partial regression or remission, prevention, slowing, or reduction of cancer remission, partial or total eradication of cancer cells, or some combination thereof.
- the phrases “patient” and “subject” are used interchangeably herein.
- a "subject in need thereof as used herein refers to a mammalian subject, preferably a human, who has been diagnosed with solid or hematologic cancer, is suspected of having solid or hematologic cancer, and/or exhibits one or more symptoms associated with solid or hematologic cancer.
- the subject may have previously received one or more therapeutic interventions for the treatment of cancer, e.g., chemotherapy.
- An "FGFR3 inhibitor” as used herein refers to any molecule that inhibits the activity of FGFR3 either partially or completely.
- An FGFR3 inhibitor may inhibit FGFR3 specifically, or it may inhibit the activity of other proteins in addition to FGFR3.
- an FGFR3 inhibitor may also inhibit the activity of other FGFRs.
- the FGFR3 inhibitor inhibits FGFR3 activity by binding to FGFR3.
- FGFR3 inhibitors include, for example, antagonistic FGFR3 antibodies or fusion proteins thereof, inactive forms of the FGFR3 ligand (e.g., truncated or otherwise mutated forms of the FGFR3 ligand) or fusion proteins thereof, small molecules, siRNAs, and aptamers.
- the FGFR3 inhibitor specifically binds FGFR3, meaning that the inhibitor exhibits little or no binding to other FGFRs.
- the FGFR3 inhibitor binds one or more FGFRs in addition to FGFR3.
- the FGFR3 inhibitor is an FGFR3 antagonist antibody, and in certain of these embodiments the FGFR3 antagonist antibody specifically binds FGFR3.
- antibody refers to an immunoglobulin molecule or an immunologically active portion thereof that binds to a specific antigen, for example FGFR3 or PD1.
- the antibody comprises two heavy chains and two light chains, with each heavy and light chain containing three complementary determining regions (CDRs).
- an antibody is an immunologically active portion of an immunoglobulin molecule
- the antibody may be, for example, a Fab, Fab', Fv, Fab' F(ab')2, disulfide-linked Fv, scFv, single domain antibody (dAb), or a diabody.
- Antibodies for use in the present methods, compositions, and kits may include natural antibodies, synthetic antibodies, monoclonal antibodies, polyclonal antibodies, chimeric antibodies, humanized antibodies, multispecific antibodies, bispecific antibodies, dual-specific antibodies, anti- idiotypic antibodies, or fragments thereof that retain the ability to bind a specific antigen, for example FGFR3 or PD1.
- an FGFR3 antibody is an IgG2 antibody.
- an FGFR3 antagonist antibody for use in the present methods, compositions, and kits comprises a heavy chain variable region comprising one or more complementary determining regions (CDRs) having the sequences set forth in SEQ ID NOs: l-3.
- the FGFR3 antagonist antibody comprises all three of these CDR sequences, and in certain of these embodiments the FGFR3 antagonist antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:4.
- the FGFR3 antagonist antibody comprises a light chain variable region comprising one or more CDRs having the sequences set forth in SEQ ID NOs:5-7.
- the FGFR3 antagonist antibody comprises all three of these CDR sequences, and in certain of these embodiments the FGFR3 antagonist antibody comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 8. In certain embodiments, the FGFR3 antagonist antibody comprises all six CDR sequences set forth in SEQ ID NOs: l-3 and 5-7, and in certain of these embodiments the FGFR3 antagonist antibody comprises the heavy chain variable region of SEQ ID NO: 4 and the light chain variable region of SEQ ID NO: 8. In certain embodiments, the antibody is B-701 comprising the heavy chain of SEQ ID NO:9 and the light chain of SEQ ID NO: 10.
- the heavy chain SEQ ID NO:9 comprises human IgGl .
- the light chain of SEQ ID NO: 10 comprises the variable region set forth in SEQ ID NO: 8 and human Ig kappa chain C (UniProt P01834).
- SEQ ID NO: 1 Hl-CDR: GFTFTSTGIS.
- SEQ ID NO:2 (H2-CDR): GRIYPTSGSTNYADSVKG.
- SEQ ID NO:3 H3-CDR: ARTYGIYDLYVDYTEYVMDY.
- SEQ ID NO:4 (Ll-CDR): RASQDVDTSLA.
- SEQ ID NO: 5 (L2-CDR): SASFLYS.
- SEQ ID NO:6 (L3-CDR): QQSTGHPQT.
- an FGFR3 antagonist antibody for use in the present methods, compositions, and kits may be PRO-001, IMC-D11, or an FGFR3 antagonistic antibody as disclosed in U.S. Patent Nos. 8,187,601 (Aveo) or 7,498,416 (Fibron).
- the FGFR3 inhibitor inhibits FGFR3 activity by binding to a ligand for FGFR3.
- FGFR3 inhibitors include, for example, antibodies that specifically bind an FGFR3 ligand or fusion proteins thereof, soluble forms of FGFR3 comprising all or part of the FGFR3 extracellular domain or fusion proteins thereof, truncated forms of FGFR3 lacking all or part of the intracellular domains required for downstream signaling or fusion proteins thereof, small molecules, siRNAs, and aptamers.
- the FGFR3 inhibitor is a pan-FGFR inhibitor, meaning that it binds to and inhibits the activity of one or more FGFRs in addition to FGFR3.
- the FGFR3 inhibitor may be a small molecule pan-FGFR inhibitor selected from the group consisting of infigratinib (BGJ398, Novartis), AZD4547 (AstraZeneca), LY2874455 (Eli Lilly), Debio 1347 (Debiopharm), ARQ 087 (ArQule), JNJ-42756493 (Janssen), and PRN1371 (Principia).
- the FGFR3 inhibitor inhibits FGFR3 activity by blocking downstream tyrosine kinase activity.
- a non-selective tyrosine kinase inhibitor such as dovitinib, lucitinib, ponatinib, nintedanib, ponatinib, or ENMD-2076 may be utilized as an FGFR3 inhibitor.
- a "PD1 inhibitor” as used herein refers to any molecule that inhibits the activity of PD1 either partially or completely.
- a PD1 inhibitor may inhibit PD1 specifically, or it may inhibit the activity of other proteins in addition to PD1.
- a PD1 inhibitor may also inhibit the activity of other immune checkpoint molecules.
- the PD1 inhibitor inhibits PD1 activity by binding to PD1.
- PD1 inhibitors include, for example, antagonistic PD1 antibodies or fusion proteins thereof, inactive forms of a PD1 ligand (e.g., truncated or otherwise mutated forms of PDL1 or PDL2) or fusion proteins thereof (e.g., AMP-224 (GlaxoSmithKline, Amplimmune), small molecules, siRNAs, and aptamers.
- the PD1 inhibitor is a PD1 antibody, and in certain of these embodiments the PD1 antagonist antibody specifically binds PD1.
- the PD1 antagonistic antibody is selected from the group consisting of nivolumab, pembrolizumab, CT-011, MEDI-0680, and RMP1-14.
- the PD1 inhibitor inhibits PD1 activity by binding to one or more ligands for PD1, i.e., PDL1 or PDL2.
- PDl inhibitors include, for example, PDl ligand antibodies or fusion proteins thereof, soluble forms of PDl comprising all or part of the PDl extracellular domain or fusion proteins thereof, truncated forms of PDl lacking all or part of the intracellular domains required for downstream signaling or fusion proteins thereof, small molecules, siRNAs, and aptamers.
- the PDl inhibitor is a PDl ligand antibody, and in certain of these embodiments the PDl ligand antibody specifically binds the PDl ligand.
- the PD l ligand antibody is selected from the group consisting of MEDI-4736, RG7446, BMS-936559,
- the FGFR3 inhibitor and PDl inhibitor are administered together as part of the same composition.
- the FGFR3 inhibitor and PD l inhibitor are administered separately, i.e., as separate compositions.
- the inhibitors may be administered simultaneously or sequentially, and may be administered via the same or different routes. In those embodiments where the inhibitors are administered sequentially, they may be administered at the same or different intervals. For example, one inhibitor may be administered more frequently than the other, or may be administered over a longer time course. In certain of these embodiments, one inhibitor may be administered one or more times prior to the first administration of the second inhibitor.
- the antibody may be administered two or more times per day, daily, two or more times per week, weekly, biweekly (i.e., every other week), every third week, or monthly. In certain embodiments, the antibody is administered weekly, bi-weekly, or every third week. In certain embodiments wherein the PDl inhibitor is a PDl antagonist antibody, the antibody may be administered two or more times per day, daily, two or more times per week, weekly, bi-weekly, every third week, or monthly. In certain embodiments, the PDl inhibitor is administered bi-weekly.
- the FGFR3 inhibitor and/or the PD l inhibitor may be administered for a specific time course determined in advance.
- the FGFR3 and/or PD l inhibitors may be administered for a time course of 1 day, 2 days, 1 week, 2 weeks, 4 weeks, or 8 weeks.
- the FGFR3 and/or PDl inhibitors may be administered indefinitely, or until a specific therapeutic benchmark is reached.
- the FGFR3 and/or PD1 inhibitors may be administered until tumor growth is arrested or reversed, until one or more tumors are eliminated, or until the number of cancer cells are reduced to a specific level.
- a "therapeutically effective amount" of a composition as used herein is an amount of a composition that produces a desired therapeutic effect in a subj ect, such as treating cancer.
- the therapeutically effective amount is an amount of the composition that yields maximum therapeutic effect.
- the composition that yields maximum therapeutic effect.
- a therapeutically effective amount yields a therapeutic effect that is less than the maximum therapeutic effect.
- a therapeutically effective amount may be an amount that produces a therapeutic effect while avoiding one or more side effects associated with a dosage that yields maximum therapeutic effect.
- a therapeutically effective amount for a particular composition will vary based on a variety of factors, including but not limited to the characteristics of the therapeutic composition (e.g., activity, pharmacokinetics,
- a therapeutically effective amount of an FGFR3 inhibitor or a PD1 inhibitor may be a dosage at which the molecule is capable of generating a therapeutic response (e.g., reducing or eliminating tumor growth) as a monotherapy, i.e., when administered alone.
- the therapeutically effective amount may be a dosage that has previously been determined to be optimal or near optimal for cancer treatment.
- the antibody may be administered at a dosage of about 10 to 50 mg/kg every two to four weeks, and in certain of these embodiments the antibody may be administered at a dosage of about 20 to 40 mg/kg every two to four weeks, or about 30 mg/kg every three weeks.
- a therapeutically effective amount of an FGFR3 inhibitor or a PD1 inhibitor may be lower than the dosage at which the molecule would normally be
- administration of the suboptimal dosage of FGFR3 or PDl inhibitor may result in decreased side effects versus the standard dosage when administered alone.
- administration of suboptimal dosage of FGFR3 or PDl inhibitors may result in decreased occurrence or severity of pruritus, colitis, or pneumonia versus administration of the optimal dosage of either inhibitor alone.
- one of an FGFR3 inhibitor and a PDl inhibitor may be administered at a dosage that has been determined to be optimal for cancer treatment when administered alone, while the other is administered at a dosage that is suboptimal for treatment when administered alone.
- the dosage of the FGFR3 inhibitor or PDl inhibitor may change over the course of the treatment regimen.
- one or both of the FGFR3 inhibitor and PDl inhibitor may be administered at higher dosage at the start of treatment (e.g., a loading phase), followed by a lower dosage later in treatment.
- An FGFR3 inhibitor, PDl inhibitor, or composition comprising both an FGFR3 inhibitor and a PDl inhibitor may be delivered to a subject by any administration pathway known in the art, including but not limited to parenteral, oral, aerosol, enteral, nasal, ophthalmic, parenteral, or transdermal (e.g., topical cream or ointment, patch).
- Parenter refers to a route of administration that is generally associated with injection, including intravenous, intraperitoneal, subcutaneous, infraorbital, infusion, intraarterial, intracapsular, intracardiac, intradermal, intramuscular, intrapulmonary, intraspinal, intrastemal, intrathecal, intrauterine, subarachnoid, subcapsular, transmucosal, or transtracheal.
- the FGFR3 inhibitor is an FGFR3 antagonist antibody, including for example B-701
- the FGFR3 inhibitor is administered intravenously.
- the PDl inhibitor is a PDl antagonist antibody
- the PDl inhibitor is administered intraperitoneally.
- FGFR3 inhibitors, PDl inhibitors, or compositions comprising both FGFR3 and PDl inhibitors may be formed into oral dosage units, such as for example tablets, pills, or capsules.
- FGFR3 inhibitor, PDl inhibitor, or FGFR3 and PDl inhibitor compositions may be administered via a time release delivery vehicle, such as, for example, a time release capsule.
- a "time release vehicle” as used herein refers to any delivery vehicle that releases active agent over a period of time rather than immediately upon administration.
- FGFR3 inhibitor, PDl inhibitor, or FGFR3 and PDl inhibitor compositions may be administered via an immediate release delivery vehicle.
- subjects receiving FGFR3 inhibitor and PDl inhibitor may receive additional therapies, including for example chemotherapy or immunotherapy, before, during, or after treatment with FGFR3 and PDl inhibitors.
- additional therapies including for example chemotherapy or immunotherapy
- the additional therapies may be administered simultaneously or sequentially with the FGFR3 inhibitor and/or PDl inhibitor.
- compositions comprising a
- compositions further comprise one or more pharmaceutically acceptable carriers, or are formulated for administration with one or more pharmaceutically acceptable carriers.
- kits comprising an FGFR3 inhibitor and a PDl inhibitor for use in carrying out the methods disclosed herein, e.g., for treating cancer.
- an FGFR3 inhibitor or PDl inhibitor may be present in the composition or kit at a dosage at which it is capable of generating a therapeutic response (e.g., reducing or eliminating tumor growth) when administered alone.
- the FGFR3 or PDl inhibitor may be present at a dosage that has previously been determined to be optimal or near optimal for cancer treatment.
- the composition or kit may be formulated to deliver a dosage of about 10 to 50 mg/kg of B-701 to the subject, and in certain of these embodiments the composition or kit may be formulated to deliver a dosage of about 20 to 40 mg/kg or about 30 mg/kg of B-701 to the subject.
- the FGFR3 or PDl inhibitor may be present at a dosage that is lower than that at which it would normally be present in a composition or kit for cancer treatment (i.e., a suboptimal dose).
- a "pharmaceutically acceptable carrier” as used herein refers to a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting a compound or molecule of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body.
- a pharmaceutically acceptable carrier may comprise a variety of components, including but not limited to a liquid or solid filler, diluent, excipient, solvent, buffer, encapsulating material, surfactant, stabilizing agent, binder, or pigment, or some combination thereof.
- Each component of the carrier must be “pharmaceutically acceptable” in that it must be compatible with the other ingredients of the composition and must be suitable for contact with any tissue, organ, or portion of the body that it may encounter, meaning that it must not carry a risk of toxicity, irritation, allergic response, immunogenicity, or any other complication that excessively outweighs its therapeutic benefits.
- Examples of pharmaceutically acceptable carriers that may be used in conjunction with the compositions provided herein include, but are not limited to, (1) sugars, such as lactose, glucose, sucrose, or mannitol; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols such as propylene glycol; (1 1) polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) dis
- compositions comprising an FGFR3 inhibitor, a PD1 inhibitor, or a combination of an FGFR3 inhibitor and a PD1 inhibitor may be formulated into a suitable dosage form, including for example solutions or suspensions in an aqueous or non-aqueous liquid, oil-in- water or water-in-oil liquid emulsions, capsules, cachets, pills, tablets, lozenges, powders, granules, elixirs or syrups, or pastilles.
- the compositions may be formulated as time release delivery vehicles, such as, for example, a time release capsule.
- a "time release vehicle” as used herein refers to any delivery vehicle that releases an active agent over a period of time rather than immediately upon administration.
- the compositions may be formulated as immediate release delivery vehicles.
- kits for carrying out the methods disclosed herein comprise an FGFR3 inhibitor and a PD1 inhibitor.
- the FGFR3 inhibitor and PD1 inhibitor may be present in the kit in a single composition. In other embodiments, the FGFR3 inhibitor and PD1 inhibitor may be present in separate compositions.
- the kits may comprise additional therapeutic or non-therapeutic compositions.
- the kits comprise instructions in a tangible medium.
- an FGFR3 inhibitor and a PD1 inhibitor for use in the treatment of cancer are also provided. Also provided are an FGFR3 inhibitor for use in the treatment of cancer in combination with a PD1 inhibitor, and a PD1 inhibitor for use in the treatment of cancer in combination with an FGFR3 inhibitor.
- an FGFR3 inhibitor and a PD 1 inhibitor in the manufacture of a medicament for treating cancer. Also provided are the use of an FGFR3 inhibitor in the manufacture of a medicament for treating cancer in combination with a PD1 inhibitor, and the use of a PD1 inhibitor in the manufacture of a medicament for treating cancer in combination with an FGFR3 inhibitor.
- Example 1 Effect of FGFR3 and immune checkpoint antagonists on solid tumor
- FGFR3 expression was verified in the FGFR3-positive MC38 mouse colorectal tumor cell line using a commercially available ELISA kit for FGFR3. Subsequently the cell line was expanded and lxlO 6 MC38 tumor cells were implanted subcutaneously into the flanks of female C57BL/6 mice that were 8 to 12 weeks of age. When tumors reached an average size of 80 - 120 mm 3 , animals were pair matched and treatment was initiated as described in Table 1.
- Group 1 control mice received PBS via twice weekly (“biwk”) intravenous administration.
- Group 2 mice received RMPl-14, a rat anti-PDl monoclonal antibody, twice weekly via interperitoneal administration at 5 mg/kg, while Group 3, 4, and 7 received BM2, a human anti-FGFR3 monoclonal antibody, either weekly ("qwk”) or twice weekly via intravenous administration at 30 mg/kg or 50 mg/kg.
- Groups 5, 6, and 8 received 5 mg/kg RMPl-14 in combination with BM2 at various dosages and frequencies.
- CTLA4 mouse anti-cytotoxic T-lymphocyte-associated antigen
- Group 9 mice received 9H10, a mouse anti-cytotoxic T-lymphocyte-associated antigen (CTLA4) monoclonal antibody via intraperitoneal administration on days 1, 4, and 7, and Group 10 received 9H10 and RMPl-14.
- CTLA4 is an immune checkpoint receptor that down-modulates the amplitude of T cell activation (Pardoll 2012).
- Antibody blockade of CTLA4 in mice has been shown to induce antitumor immunity.
- CTLA4 antibody ipilimumab has been approved for treatment of advanced melanoma and is currently under development for the treatment of various other cancer types including prostate and lung cancers, while the CTLA4 antibody tremelimumab is currently under development for the treatment of melanoma (Grosso & Jure-Kunkel 2013).
- Tumor volume was monitored twice weekly using caliper measurements, and the results from all animals on study D18 are summarized in Fig. 1.
- Fig. 2 is a snapshot of D14 study results taken after study termination, and includes data only from animals that either completed the study or were removed due to tumor progression. Fig. 2 highlights the B-701 and B-701 combination treatment groups at the 7 and 14 day dosing time points as these were selected for the subsequent study in Example 2 to examine immune cell infiltration.
- FGFR3 inhibition has previously been shown to decrease immune response. Since PD1 inhibition is believed to inhibit cancer cell growth by upregulating T cell response to cancer cells, one of ordinary skill in the art would not have expected administration of an FGFR3 inhibitor to increase the anti-cancer effects of PD1. Surprisingly, however, mice administered a combination of BM2 at 30 mg/kg twice weekly or 50 mg/kg weekly or and RMPl-14 (Groups 5, 6, and 8) exhibited markedly slower tumor growth over 18 days than mice administered either antibody alone (Groups 2-4). Although more potent effects were observed when RMPl-14 was combined with 9H10, this combination is likely to be poorly tolerated in at least some patients, making alternative combinations such as FGFR3 inhibitor and PD 1 inhibitor clinically important.
- FGFR3 mutation and expression have been shown to be associated with a non- inflamed tumor phenotype in bladder cancer, and thus may be indicative of a tumor that is unlikely to respond to an immune checkpoint inhibitor (Sweiss 2015).
- Blockade of FGFR3 activity by an agent such as BM2 could improve the immune status of the tumor and make the tumor more likely to respond to checkpoint inhibitors.
- treatment with BM2 may be carried prior to or both prior to and concurrent with treatment with a checkpoint inhibitor.
- Example 2 Effect of FGFR3 antagonist on immune cell infiltration
- Group 1 control mice received PBS via twice weekly ("biwk") intravenous administration while Group 2 mice received B-701 twice weekly via intravenous administration at 30 mg/kg.
- Group 2 mice received B-701 twice weekly via intravenous administration at 30 mg/kg.
- 3 animals from each treatment group were sacrificed and tumors were collected.
- Half of the tumor was processed for paraffin embedding while the second half was used to prepare a single cell suspension and processed for flow cytometry the results of which are shown in Table 2.
- Example 3 Effect of FGFR3 and immune checkpoint antagonists on lung tumor development
- FGFR3 expression was verified in the FGFR3-positive Madison 109 and Lewis Lung Carcinoma mouse lung cancer cell lines using a commercially available ELISA kit for FGFR3. Subsequently, the cell lines were expanded and 1 x 10 6 Lewis Lung Carcinoma tumor cells were implanted subcutaneously into the flanks of female C57BL/6 mice that were 8 to 12 weeks of age. Additionally, 1 x 10 6 Madisonl09 tumor cells were implanted subcutaneously into the flanks of CR female BALB/c mice that were 8 to 12 weeks of age.
- mice were pair matched and treatment was initiated as described in Table 3 for mice bearing Lewis Lung Carcinoma tumors and Table 4 for mice bearing Madisonl09 tumors. Tumors were measured using calipers twice weekly. After 7 and 14 days of treatment, three mice from each group were sacrificed and tumors were processed for histology (half of each tumor was embedded in paraffin and the other half was frozen in Optimal Cutting Temperature (O.C.T.) Compound). The remaining animals were dosed as indicated and sacrificed at day 21 (Madison 109) or day 22 (Lewis Lung Carcinoma). [0073] Table 3: Lewis Lung Carcinoma treatment regimen
- Fig. 3 Lewis Lung Carcinoma tumor bearing mice
- Fig. 4 Medison 109 tumor bearing mice
- the greatest efficacy was observed when anti-PD-1 and B-701 were combined, further supporting that antagonism of FGFR3 enhances the effect of immune checkpoint inhibition.
- the combined treatment actually resulted in significantly better tumor growth inhibition at day 8 of the study (see Fig. 3, line with diamonds).
- combination treatment was the only regimen that resulted in tumor growth suppression significant from the vehicle group (see Fig. 3, line with diamonds).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11201706727XA SG11201706727XA (en) | 2015-02-19 | 2016-02-19 | Methods, compositions, and kits for treatment of cancer |
CN201680022780.7A CN107635583A (en) | 2015-02-19 | 2016-02-19 | For the method for the treatment of cancer, composition and kit |
KR1020177025882A KR20170137717A (en) | 2015-02-19 | 2016-02-19 | Methods, compositions, and kits for the treatment of cancer |
JP2017544657A JP6774421B2 (en) | 2015-02-19 | 2016-02-19 | Methods, Compositions, and Kits for the Treatment of Cancer |
MX2017010595A MX2017010595A (en) | 2015-02-19 | 2016-02-19 | Methods, compositions, and kits for treatment of cancer. |
CA2976638A CA2976638A1 (en) | 2015-02-19 | 2016-02-19 | Methods, compositions, and kits for treatment of cancer |
BR112017017700A BR112017017700A2 (en) | 2015-02-19 | 2016-02-19 | cancer treatment methods, compositions and kits |
EP16753128.4A EP3258966A4 (en) | 2015-02-19 | 2016-02-19 | Methods, compositions, and kits for treatment of cancer |
AU2016219917A AU2016219917B2 (en) | 2015-02-19 | 2016-02-19 | Methods, compositions, and kits for treatment of cancer |
IL253979A IL253979B (en) | 2015-02-19 | 2017-08-14 | Methods, compositions, and kits for treatment of cancer |
AU2022200196A AU2022200196A1 (en) | 2015-02-19 | 2022-01-13 | Methods, compositions, and kits for treatment of cancer |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562118350P | 2015-02-19 | 2015-02-19 | |
US62/118,350 | 2015-02-19 | ||
US201562150235P | 2015-04-20 | 2015-04-20 | |
US62/150,235 | 2015-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016134234A1 true WO2016134234A1 (en) | 2016-08-25 |
Family
ID=56689191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/018634 WO2016134234A1 (en) | 2015-02-19 | 2016-02-19 | Methods, compositions, and kits for treatment of cancer |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160243228A1 (en) |
EP (1) | EP3258966A4 (en) |
JP (2) | JP6774421B2 (en) |
KR (1) | KR20170137717A (en) |
CN (1) | CN107635583A (en) |
AU (2) | AU2016219917B2 (en) |
BR (1) | BR112017017700A2 (en) |
CA (1) | CA2976638A1 (en) |
IL (1) | IL253979B (en) |
MX (1) | MX2017010595A (en) |
SG (1) | SG11201706727XA (en) |
WO (1) | WO2016134234A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10272087B2 (en) | 2012-05-30 | 2019-04-30 | Astex Therapeutics Ltd | Pteridines as FGFR inhibitors |
US10421747B2 (en) | 2014-03-26 | 2019-09-24 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as FGFR kinase modulators |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
US10519137B2 (en) | 2010-04-30 | 2019-12-31 | Astex Therapeutics Ltd | Pyrazolyl quinoxaline kinase inhibitors |
US10716787B2 (en) | 2014-03-26 | 2020-07-21 | Astex Therapeutics Ltd | Combinations |
US10736900B2 (en) | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
EP3576792A4 (en) * | 2017-02-06 | 2020-09-09 | Fusion Pharmaceuticals Inc. | Methods, compositions, and kits for treatment of cancer |
US10898482B2 (en) | 2015-02-10 | 2021-01-26 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
WO2021058798A1 (en) * | 2019-09-26 | 2021-04-01 | Janssen Pharmaceutica Nv | Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings |
US11155555B2 (en) | 2015-09-23 | 2021-10-26 | Janssen Pharmaceutica Nv | Compounds |
US11505611B2 (en) | 2020-08-21 | 2022-11-22 | Genzyme Corporation | FGFR3 antibodies and methods of use |
US11542247B2 (en) | 2015-09-23 | 2023-01-03 | Janssen Pharmaceutica Nv | Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer |
EP3930705A4 (en) * | 2019-03-01 | 2023-09-06 | Fusion Pharmaceuticals Inc. | Methods and compositions for treating cancer |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI1006448B1 (en) | 2009-03-25 | 2021-08-17 | Genentech, Inc | ANTI-FGFR3 ANTAGONIST ANTIBODY, MONOCLONAL ANTIBODY, POLYNUCLEOTIDE, VECTOR, TRANSGENIC MICROORGANISM, METHOD FOR THE PRODUCTION OF AN ANTI-FGFR3 ANTIBODY, PHARMACEUTICAL FORMULATION AND USES OF ANTI-FR3 ANTAGONIST ANTIBODY |
CN108440673B (en) * | 2018-04-08 | 2021-08-17 | 海南医学院 | Fc fusion protein PD1/FGFR1 and application thereof |
CN113710244A (en) * | 2019-06-03 | 2021-11-26 | 融合制药公司 | Methods and compositions for treating cancer |
TW202233185A (en) * | 2020-10-28 | 2022-09-01 | 日商衛材R&D企管股份有限公司 | Pharmaceutical composition for treating tumors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100247531A1 (en) * | 2009-03-25 | 2010-09-30 | Genentech, Inc. | Anti-fgfr3 antibodies and methods using same |
US20140030259A1 (en) * | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
US20140243308A1 (en) * | 2010-12-22 | 2014-08-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
WO2015009856A2 (en) * | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR073770A1 (en) * | 2008-10-20 | 2010-12-01 | Imclone Llc | ISOLATED ANTIBODY THAT LINKS SPECIFICALLY WITH, AND INDUCES THE DEGRADATION OF THE RECEPTOR-3 OF THE HUMAN FIBROBLAST GROWTH FACTOR (FGFR-3), FGFR-3 HUMAN LINK FRAGMENT OF THE SAME, PHARMACEUTICAL COMPOSITION AND PRODUCT COMPOSITION |
AR091649A1 (en) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
-
2016
- 2016-02-19 EP EP16753128.4A patent/EP3258966A4/en not_active Withdrawn
- 2016-02-19 CA CA2976638A patent/CA2976638A1/en active Pending
- 2016-02-19 US US15/048,030 patent/US20160243228A1/en not_active Abandoned
- 2016-02-19 SG SG11201706727XA patent/SG11201706727XA/en unknown
- 2016-02-19 AU AU2016219917A patent/AU2016219917B2/en active Active
- 2016-02-19 MX MX2017010595A patent/MX2017010595A/en unknown
- 2016-02-19 WO PCT/US2016/018634 patent/WO2016134234A1/en active Application Filing
- 2016-02-19 JP JP2017544657A patent/JP6774421B2/en active Active
- 2016-02-19 KR KR1020177025882A patent/KR20170137717A/en not_active Application Discontinuation
- 2016-02-19 CN CN201680022780.7A patent/CN107635583A/en active Pending
- 2016-02-19 BR BR112017017700A patent/BR112017017700A2/en active Search and Examination
-
2017
- 2017-08-14 IL IL253979A patent/IL253979B/en active IP Right Grant
-
2020
- 2020-10-02 JP JP2020167443A patent/JP7122357B2/en active Active
-
2022
- 2022-01-13 AU AU2022200196A patent/AU2022200196A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100247531A1 (en) * | 2009-03-25 | 2010-09-30 | Genentech, Inc. | Anti-fgfr3 antibodies and methods using same |
US20140243308A1 (en) * | 2010-12-22 | 2014-08-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
US20140030259A1 (en) * | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
WO2015009856A2 (en) * | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
Non-Patent Citations (1)
Title |
---|
See also references of EP3258966A4 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10519137B2 (en) | 2010-04-30 | 2019-12-31 | Astex Therapeutics Ltd | Pyrazolyl quinoxaline kinase inhibitors |
US10272087B2 (en) | 2012-05-30 | 2019-04-30 | Astex Therapeutics Ltd | Pteridines as FGFR inhibitors |
US10421747B2 (en) | 2014-03-26 | 2019-09-24 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as FGFR kinase modulators |
US10716787B2 (en) | 2014-03-26 | 2020-07-21 | Astex Therapeutics Ltd | Combinations |
US10736900B2 (en) | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
US11918576B2 (en) | 2014-03-26 | 2024-03-05 | Astex Therapeutics Ltd | Combination of an FGFR inhibitor and a CMET inhibitor |
US10898482B2 (en) | 2015-02-10 | 2021-01-26 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
US11684620B2 (en) | 2015-02-10 | 2023-06-27 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
US11155555B2 (en) | 2015-09-23 | 2021-10-26 | Janssen Pharmaceutica Nv | Compounds |
US11542247B2 (en) | 2015-09-23 | 2023-01-03 | Janssen Pharmaceutica Nv | Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer |
EP3576792A4 (en) * | 2017-02-06 | 2020-09-09 | Fusion Pharmaceuticals Inc. | Methods, compositions, and kits for treatment of cancer |
EP3930705A4 (en) * | 2019-03-01 | 2023-09-06 | Fusion Pharmaceuticals Inc. | Methods and compositions for treating cancer |
WO2021058798A1 (en) * | 2019-09-26 | 2021-04-01 | Janssen Pharmaceutica Nv | Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings |
US11505611B2 (en) | 2020-08-21 | 2022-11-22 | Genzyme Corporation | FGFR3 antibodies and methods of use |
Also Published As
Publication number | Publication date |
---|---|
BR112017017700A2 (en) | 2018-07-31 |
JP2018507220A (en) | 2018-03-15 |
CA2976638A1 (en) | 2016-08-25 |
EP3258966A1 (en) | 2017-12-27 |
US20160243228A1 (en) | 2016-08-25 |
JP7122357B2 (en) | 2022-08-19 |
IL253979B (en) | 2021-06-30 |
CN107635583A (en) | 2018-01-26 |
MX2017010595A (en) | 2018-11-12 |
KR20170137717A (en) | 2017-12-13 |
AU2016219917A1 (en) | 2017-09-07 |
EP3258966A4 (en) | 2018-07-25 |
SG11201706727XA (en) | 2017-09-28 |
AU2022200196A1 (en) | 2022-02-10 |
IL253979A0 (en) | 2017-10-31 |
JP6774421B2 (en) | 2020-10-21 |
AU2016219917B2 (en) | 2021-12-16 |
JP2021020909A (en) | 2021-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016219917B2 (en) | Methods, compositions, and kits for treatment of cancer | |
JP7507209B2 (en) | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer | |
TWI780994B (en) | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer | |
EP3102604B1 (en) | Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer | |
CN105451770B (en) | Treatment of cancer using a combination of a PD-1 antagonist and dinaciclib | |
WO2015119930A1 (en) | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer | |
US20200308286A1 (en) | Methods, compositions, and kits for treatment of cancer | |
KR20230006568A (en) | Triple combination therapy to enhance cancer cell death in cancers with low immunogenicity | |
JP2022184998A (en) | Combination of ramucirumab and pembrolizumab for treatment of certain cancers | |
CN111973739B (en) | Use of anti-PD-L1 monoclonal antibodies for the treatment of cancer | |
CN116406288A (en) | Methods for treating cancer or von-hippel-lindau disease using a combination of a PD-1 antagonist, a HIF-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof | |
US20230250182A1 (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof | |
CN117202934A (en) | Use of anti-PD-1 antibodies in combination with first-line chemotherapy for treatment of advanced non-small cell lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16753128 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2976638 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 253979 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2017544657 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 122021015416 Country of ref document: BR Ref document number: 11201706727X Country of ref document: SG Ref document number: MX/A/2017/010595 Country of ref document: MX |
|
REEP | Request for entry into the european phase |
Ref document number: 2016753128 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017017700 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2016219917 Country of ref document: AU Date of ref document: 20160219 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20177025882 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112017017700 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170817 |